Together, MLL3 and SET1A may act in a dual mode in ER-positive and tamoxifen-resistant breast cancer cells to confer ER-dependent breast cancer cell-growth, which could be therapeutically exploited by employing ERα antagonists, such as fulvestrant (Fig. 4). Here, SETD1A is linked to breast carcinoma.